From The Bio Report/Daniel Levine: "Despite a rapid advance of technology there’s been little change in the preclinical drug development process. Vium is hoping to change that by using sensors, automation, and bioinformatics to change the way data is gathered in the preclinical process to fuel better and faster decisions about the potential value of [...]
From Bloomberg: "Bill Maris, CEO Google Ventures, comments on artificial intelligence's impact on biotech, the prospects for Theranos and the venture capital environment. He speaks with Bloomberg's Emily Chang on "Bloomberg West" from the Bloomberg Technology Conference in San Francisco."
From Merck press release: "Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for [...]
From the new report from California Life Sciences Institute on the economic strength/aspects of Bay Area life science startups: "OVERVIEW Pre-Series A life science companies in the Bay Area are significantly impacting the local and state economy. This is the key finding of a survey of 137 Bay Area life science startups conducted by the California [...]
From Bloomberg Video: "Jessica Mega, Verily Life Sciences chief medical officer, discusses the company's breakthrough biotech goals and life sciences funding with Bloomberg's Emily Chang on 'Bloomberg West.'"
From KQED/Forum with Michael Krasny: "In just 20 years, most people in developed countries won’t have sex to procreate. That’s what Stanford law professor and bioethicist Hank Greely predicts: a future where skin cells can be used to make an embryo and parents would prefer a baby made in a laboratory rather than the bedroom. In [...]
Coverage of StemCells, Inc. ceasing operations: Xconomy: "StemCells (NASDAQ: STEM) has decided to close up shop after its most advanced therapy didn’t do enough in a Phase 2 trial to improve people with spinal cord injuries. The one-time stem cell pioneer will wind down operations with $5.5 million in the bank, as of May 31, [...]
The latest coverage of the mounting issues for Theranos: Fortune: Theranos Is Now Facing a Class Action Lawsuit Accusing It of Consumer Fraud More Wall Street Journal: Craving Growth, Walgreens Dismissed Its Doubts About Theranos (subscr) More The Verge: Walgreens brought Theranos to its stores without even testing the technology More Vanity Fair: Elizabeth Holmes’s Theranos [...]
From Daniel Levine/RAREcast: "Researchers’ understanding of certain rare diseases is changing as new sequencing technology is providing new views of the genome. A group of diseases collectively known as repeat expansion disorders including Fragile X Syndrome, Freidrich’s Ataxia, and Huntington’s disease are being viewed in new ways thanks to the ability to read long fragments [...]
More from CNBC: Anacor shares soar 57% on $5.2B Pfizer acquisition "Shares of Anacor Pharmaceuticals spiked more than 57 percent Monday after it agreed to be bought by pharma giant Pfizer. Pfizer is buying Anacor in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after the U.S. drug major [...]